期刊
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
卷 19, 期 1, 页码 81-86出版社
SPRINGER JAPAN KK
DOI: 10.1007/s10147-013-0529-6
关键词
TJ-48; Regulatory T cell; Tumor immunity; Kampo medicine; Pancreatic cancer
类别
资金
- Grants-in-Aid for Scientific Research [23592010, 24890149, 24791426] Funding Source: KAKEN
Background The prognosis of pancreatic cancer is extremely poor regardless of various combination therapies. Immunoaugumentation against tumor cells was recently A focus. We reported that the population of Foxp3(+)CD25(+)CD4(+) regulatory T cells (Foxp3(+)Treg) was the new parameter for the estimation of host immunity and had correlation with tumor aggressiveness. Here we show the immunoaugumentation effects of Japanese Kampo medicine, Juzen-Taihoto/TJ-48, empirically considered as an immunoaugumentation drug, with investigation of Treg and other immunological parameters. Patients and method Peripheral Foxp3(+)Treg populations, CD4/CD8 ratio, and CD57(+) cells (NK cells) populations in advanced pancreatic cancer patients (n = 30, stage VI A and B according to TNM classification) were estimated after TJ-48 administration for 14 days before the anti-cancer therapy. Results Treg populations were significantly increased compared to healthy donors (Mann-Whitney U test, P < 0.001). Administration of Juzen-Taihoto/TJ-48 significantly decreased Treg populations (Mann-Whitney U test, P < 0.001) and increased the CD4/CD8 ratio (Mann-Whitney U test, P < 0.01), even though CD57(+) cell populations did not change significantly. Conclusions Juzen-Taihoto/TJ-48 increased regulatory activities in T cells through decreasing Foxp3(+)Treg populations in advanced pancreatic cancer patients. This effect can lead to immunoaugumentation for various combination therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据